UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000059943 |
|---|---|
| Receipt number | R000068545 |
| Scientific Title | Effects of consumption of the test food on cognitive function: a randomized, placebo-controlled, double-blind, parallel-group comparison study |
| Date of disclosure of the study information | 2025/12/02 |
| Last modified on | 2025/12/02 12:17:10 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects of consumption of the test food on cognitive function
Acronym
Effects of consumption of the test food on cognitive function
Scientific Title
Effects of consumption of the test food on cognitive function: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Scientific Title:Acronym
Effects of consumption of the test food on cognitive function
Region
| Japan |
Condition
Condition
Healthy Japanese
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To verify the effects of consumption of the test food on cognitive function in healthy Japanese aged 40 years or older.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Primary cognitive function test
Key secondary outcomes
Secondary cognitive function tests, peripheral blood tests, urinalysis, physical measurements, and adverse events
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Institution is not considered as adjustment factor.
Blocking
YES
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Duration: 12 weeks
Test product: Test food
Administration: Three capsules/pack/day
Interventions/Control_2
Duration: 12 weeks
Test product: Placebo food
Administration: Three capsules/pack/day
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Japanese
2. Men or women
3. Participants aged 40 years or older
4. Healthy participants
5. Participants whose Mini-Mental State Examination (MMSE) score is 24 or higher at screening
6. Participants who have a "yes" in the validity indicator of Cognitrax on both verbal memory and visual memory at screening
7. Participants who meet inclusion criteria 1-6 and have a low standardized score for Verbal Memory on Cognitrax at screening
Key exclusion criteria
Participants who
1. are undergoing treatment or have a history of malignant tumor, heart failure, or myocardial infarction
2. have a pacemaker or an implantable cardioverter defibrillator
3. are undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. are taking Foods for Specified Health Uses or Foods with Functional Claims
5. are taking or using medicines (including herbal medicines) or supplements
6. are allergic to medicines or foods related to the test product
7. have dementia
8. have mental health issues such as depression disorder, attention deficit/hyperactivity disorder, or other issues
9. are taking foods or supplements that may affect cognitive function, such as docosahexaenoic acid, eicosapentaenoic acid, ginkgo leaf extract, tocotrienols, astaxanthin, gamma-aminobutyric acid, phosphatidylserine, or plasmalogens
10. are taking blue-backed fish such as sardines, mackerel, or saury at least four times a week
11. use devices, equipment, and applications that may affect cognitive functions (e.g., brain training puzzles, brain training games)
12. currently smoke or have quit smoking within one year prior to providing consent for this study
13. drink alcoholic beverages excessively
14. are on a diet or engage in strenuous exercise for the purpose of physical strengthening
15. have an irregular lifestyle due to shift work or other reasons
16. are taking anticoagulants such as warfarin
17. are pregnant, lactating, or planning to become pregnant during this study
18. have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study
19. are judged as ineligible to participate in this study by the physician
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Organization
Medical Corporation Seishinkai, Takara Clinic
Division name
Director
Zip code
141-0022
Address
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
TEL
03-5793-3623
t-takara@takara-clinic.com
Public contact
Name of contact person
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
Organization
ORTHOMEDICO Inc.
Division name
R&D Department
Zip code
112-0002
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan
TEL
03-3818-0610
Homepage URL
nao@orthomedico.jp
Sponsor or person
Institute
Euglena Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Euglena Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
Tel
03-5793-3623
IRB@takara-clinic.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 12 | Month | 02 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2025 | Year | 11 | Month | 26 | Day |
Date of IRB
| 2025 | Year | 11 | Month | 26 | Day |
Anticipated trial start date
| 2025 | Year | 12 | Month | 02 | Day |
Last follow-up date
| 2026 | Year | 06 | Month | 22 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
<Statistical analysis details>
Subgroups will be defined based on the factors in the following variables.
Age: >= / < median
Cognitive function tests: >= / < median
Cognitive function tests (standardized score): Average / Low average / Low
Peripheral blood tests: >= / < median
n-3 fatty acids: >= / < the adequate intake for n-3 fatty acids in the Japanese Dietary Reference Intakes (2025 Edition)
Final education: subgroup analysis by final education
Field of study: subgroup analysis by field of study
Subjective symptoms related to cognitive decline: by each response option
Daily sleep duration during the intervention period: >= / < median
Number of days feeling stress during the intervention period: >= < median
Number of days feeling fatigue during the intervention period: >= / < median
Management information
Registered date
| 2025 | Year | 12 | Month | 02 | Day |
Last modified on
| 2025 | Year | 12 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000068545
